Vonoprazan
- Generic Name
- Vonoprazan
- Brand Names
- Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16FN3O2S
- CAS Number
- 881681-00-1
- Unique Ingredient Identifier
- 1R5L3J156G
- Background
Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H, K-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pump inhibitors, PCABs are not affected by CYP2C19 genetic polymorphisms and do not require acid-resistant formulations. Furthe...
- Indication
Vonoprazan, in combination with amoxicillin and clarithromycin in a co-packaged product, is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. Another co-packaged product with only vonoprazan and amoxicillin is also indicated for the treatment of H. pylori infection in adults.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastric or Duodenal Ulcers Caused by Low-dose Aspirin, Helicobacter Pylori Infection, Reflux Esophagitis (RE), Develop NSAID-induced gastric ulcers
- Associated Therapies
- -
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Xiuli Zuo
- Target Recruit Count
- 30
- Registration Number
- NCT06731023
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 728
- Registration Number
- NCT06660342
- Locations
- 🇺🇸
PPD, Wilmington, North Carolina, United States
High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT06561698
- Locations
- 🇨🇳
Hebi People's Hospital, Hebi, Henan, China
🇨🇳Jiaozuo People's Hospital, Jiaozuo, Henan, China
🇨🇳Luoyang central Hospital, Luoyang, Henan, China
Optimization of Minocycline for Helicobacter Pylori Rescue Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 476
- Registration Number
- NCT06561711
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Songjiang Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Shicai Ye
- Target Recruit Count
- 196
- Registration Number
- NCT06526455
- Locations
- 🇨🇳
Yellow River Sanmenxia Hospital, Sanmenxia, Henan, China
🇨🇳The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
🇨🇳Maoming People's Hospital, Maoming, Guangdong, China
Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 558
- Registration Number
- NCT06514274
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06391177
- Locations
- 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Target Recruit Count
- 100
- Registration Number
- NCT06340724
- Locations
- 🇨🇳
Nanjing First Hospitai, Nanjing, Jiangsu, China
Effect of Gut Microbiota After High-dose Dual Therapy Combined With Probiotics for Helicobacter Pylori Eradication
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT06292546
- Locations
- 🇨🇳
Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China
Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Yongquan Shi
- Target Recruit Count
- 688
- Registration Number
- NCT06168084
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.